Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigating the role of growth hormone in hepatic lipid metabolism in humans
2020-000831-34Phase 2Active
- Sponsor
- Medical University of Vienna
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of somatropin and pegvisomant, sponsored by Medical University of Vienna. Primary endpoint: GH induced changes in hepatic ATP turnover. Started Dec 2021; status: active.
02
Drugs
somatropinpegvisomant
Beyond the preview
Go deeper on 2020-000831-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000831-34.